We are live on
!
Find out more
Handelsbanken Fonder Portfolio holdings
AUM
$35.1B
1-Year Est. Return
47.76%
This Fund
S&P 500
This Quarter
Est. Return
+2.36%
1 Year Est. Return
+47.76%
3 Year Est. Return
+137.96%
5 Year Est. Return
+170.36%
10 Year Est. Return
+934.7%
AUM
$26.2B
AUM Growth
+$914M
(+3.6%)
Cap. Flow
+$1.01B
Cap. Flow
% of AUM
3.87%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
1,591
New
69
Increased
817
Reduced
431
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$107M |
| 2 |
EXL Service
EXLS
|
+$72M |
| 3 |
Apple
AAPL
|
+$64.3M |
| 4 |
Synopsys
SNPS
|
+$56.8M |
| 5 |
ServiceNow
NOW
|
+$54.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halozyme
HALO
|
+$74.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$53.5M |
| 3 |
Edwards Lifesciences
EW
|
+$45M |
| 4 |
Abbott
ABT
|
+$40.3M |
| 5 |
Rockwell Automation
ROK
|
+$39.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.4% |
| 2 | Healthcare | 16.63% |
| 3 | Financials | 12.04% |
| 4 | Communication Services | 9.47% |
| 5 | Industrials | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1351
Kohl's
KSS
$2.19B
| $425K | ﹤0.01% |
30,294
-11,100
| -27% | -$191K |
|
1352
Privia Health
PRVA
$2.75B
| $424K | ﹤0.01% |
21,700
| – | – |
|
1353
Myriad Genetics
MYGN
$309M
| $422K | ﹤0.01% |
30,788
+3,500
| +13% | +$64.6K |
|
|
HTLF
1354
DELISTED
Heartland Financial USA, Inc.
HTLF
| $419K | ﹤0.01% |
6,837
+300
| +5% | +$18.8K |
|
1355
Helios Technologies
HLIO
$2.66B
| $418K | ﹤0.01% |
9,358
+1,600
| +21% | +$79.2K |
|
1356
ePlus
PLUS
$2.32B
| $417K | ﹤0.01% |
5,644
| – | – |
|
1357
Helen of Troy
HELE
$696M
| $416K | ﹤0.01% |
6,951
-400
| -5% | -$26.6K |
|
1358
Gentherm
THRM
$1.27B
| $416K | ﹤0.01% |
10,416
+2,300
| +28% | +$96.4K |
|
1359
Lakeland Financial Corp
LKFN
$1.55B
| $415K | ﹤0.01% |
6,030
| – | – |
|
|
OPRA
1360
Opera Ltd
OPRA
$1.78B
| $415K | ﹤0.01% |
21,900
+600
| +3% | +$10.7K |
|
1361
Veeco
VECO
$3.26B
| $415K | ﹤0.01% |
+15,500
| New | +$450K |
|
|
PMT
1362
PennyMac Mortgage Investment
PMT
$827M
| $413K | ﹤0.01% |
32,811
| – | – |
|
1363
Under Armour
UAA
$2.26B
| $413K | ﹤0.01% |
49,900
-2,800
| -5% | -$25.6K |
|
|
IBTX
1364
DELISTED
Independent Bank Group, Inc.
IBTX
| $413K | ﹤0.01% |
6,800
| – | – |
|
1365
Fortrea Holdings
FTRE
$1.74B
| $412K | ﹤0.01% |
22,100
-2,000
| -8% | -$39K |
|
1366
TripAdvisor
TRIP
$1.26B
| $412K | ﹤0.01% |
27,900
-4,000
| -13% | -$58.5K |
|
1367
STAAR Surgical
STAA
$1.27B
| $411K | ﹤0.01% |
16,900
| – | – |
|
|
CSGS
1368
DELISTED
CSG Systems International
CSGS
| $410K | ﹤0.01% |
8,030
+1,100
| +16% | +$56.6K |
|
1369
Life Time Group Holdings
LTH
$9.79B
| $407K | ﹤0.01% |
18,400
+1,100
| +6% | +$26.3K |
|
|
JOYY
1370
JOYY Inc
JOYY
$3.74B
| $406K | ﹤0.01% |
9,700
+2,200
| +29% | +$80.8K |
|
1371
AC Immune
ACIU
$267M
| $405K | ﹤0.01% |
150,000
| – | – |
|
1372
CTS Corp
CTS
$1.82B
| $405K | ﹤0.01% |
7,685
+500
| +7% | +$26.2K |
|
1373
Intellia Therapeutics
NTLA
$1.69B
| $405K | ﹤0.01% |
34,700
+2,300
| +7% | +$35.9K |
|
1374
Oxford Industries
OXM
$538M
| $404K | ﹤0.01% |
5,126
| – | – |
|
1375
Marqeta
MQ
$1.63B
| $402K | ﹤0.01% |
26,525
+2,675
| +11% | +$47K |
|
Similar funds
VIA
Handelsbanken Fonder's Q4 2024 Portfolio in Review
As of Q4 2024, Handelsbanken Fonder held 1,591 positions worth $26.2B, up 3.6% from $25.3B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Handelsbanken Fonder deployed $1.01B of net new capital in Q4 2024, opening 69 new positions and adding to 817 existing holdings. Its largest new stake was GE Vernova: 105,537 shares worth $34.7M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 35% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Halozyme, an estimated $74.5M trimmed.
- Handelsbanken Fonder's largest Q4 2024 buy was GE Vernova: 105,537 shares worth $34.7M.
- Handelsbanken Fonder added most to Microsoft in Q4 2024, an estimated $107M increase.
- Handelsbanken Fonder's biggest Q4 2024 reduction was Halozyme, cutting an estimated $74.5M.
- Handelsbanken Fonder fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $5.92M.
- Handelsbanken Fonder's ten largest holdings make up 33% of its $26.2B portfolio in Q4 2024.
- Handelsbanken Fonder opened 69 new positions and closed 49 in Q4 2024.
- Handelsbanken Fonder's portfolio value rose 3.6% quarter-over-quarter to $26.2B.
Based on Handelsbanken Fonder's 13F filing for Q4 2024, filed 3 Feb 2025.